Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 1:13 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1009–1032 of 1,208 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Study Powder Clear all

Conditions: Asthma
Interventions: VR506; Drug
Lead sponsor: Vectura Limited; Industry
Eligibility: 12 Years to 65 Years
Enrollment: 197 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 11
States / cities: Los Angeles, California • Denver, Colorado • Celebration, Florida + 8 more

Conditions: Asthma
Interventions: RELVAR/BREO, Salbutamol, Smart phone app, HCP Dashboard, Sensors; Drug · Device
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 437 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 11
States / cities: Aventura, Florida • Miami, Florida • Flossmoor, Illinois + 8 more

Conditions: Infection, Human Immunodeficiency Virus
Interventions: GSK2838232, Placebo, Ritonavir; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Advanced Solid Tumor
Interventions: PM14; Drug
Lead sponsor: PharmaMar; Industry
Eligibility: 18 Years and older
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 2
States / cities: Boston, Massachusetts • Houston, Texas

Conditions: Environmental Enteric Dysfunction, Zinc Deficiency
Interventions: Micronutrient Powder (MNP) + 15 mg Zn, MNP + 10 mg Zn, MNP + 5 mg Zn, MNP without Zn; Dietary Supplement
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Months to 24 Months
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Type 1 Diabetes
Interventions: Metformin (glucophage), oral placebo; Drug · Other
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 12 Years to 19 Years
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Non-small Cell Lung Cancer
Interventions: PDR001, Cisplatin, Gemcitabine, Pemetrexed, Carboplatin, Paclitaxel, Canakinumab; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 5
States / cities: Fayetteville, Arkansas • Santa Monica, California • Stanford, California + 2 more

Conditions: Relapsed/Refractory Multiple Myeloma
Interventions: Plitidepsin, Dexamethasone; Drug
Lead sponsor: PharmaMar; Industry
Eligibility: 18 Years and older
Enrollment: 255 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2017
U.S. locations: 5
States / cities: Tuscaloosa, Alabama • Los Angeles, California • Jacksonville, Florida + 2 more

Conditions: Acute Kidney Injury Due to Sepsis
Interventions: TIN816 70 mg lyophilisate powder, Placebo; Biological · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 316 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 19
States / cities: Birmingham, Alabama • San Francisco, California • Stanford, California + 14 more

Conditions: Schizophrenia
Interventions: D-serine; Drug
Lead sponsor: Nathan Kline Institute for Psychiatric Research; Other
Eligibility: 18 Years to 60 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 3
States / cities: New Haven, Connecticut • Glen Oaks, New York • Orangeburg, New York

Conditions: Advanced Malignancies
Interventions: Alisertib; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Newly Diagnosed and Recurrent Glioblastoma
Interventions: [177Lu]Lu-NeoB, [68Ga]Ga-NeoB, Temozolomide; Drug · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 6
States / cities: Los Angeles, California • Aurora, Colorado • Boston, Massachusetts + 3 more

Conditions: Pulmonary Arterial Hypertension
Interventions: GB002 (seralutinib), Generic Dry Powder Inhaler; Drug · Device
Lead sponsor: Gossamer Bio USA, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 15
States / cities: Sacramento, California • Santa Barbara, California • Jacksonville, Florida + 11 more

Conditions: Eosinophilic Esophagitis
Interventions: IRL201104, Placebo; Drug
Lead sponsor: Revolo Biotherapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 23
States / cities: Little Rock, Arkansas • Murrieta, California • Centennial, Colorado + 19 more

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Indacaterol 150 µg, Salmeterol 50 µg, Placebo to indacaterol, Placebo to salmeterol; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 40 Years and older
Enrollment: 1,123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 74
States / cities: Anniston, Alabama • Fairhope, Alabama • Jasper, Alabama + 69 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: NVA237 12.5 µg once daily, NVA237 25.0 µg once daily, NVA237 12.5 µg twice daily, NVA237 50.0 µg once daily, NVA237 25.0 µg twice daily, NVA237 100.0 µg once daily, NVA237 50.0 µg twice daily, Placebo to NVA237 once daily; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 40 Years and older
Enrollment: 388 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 6
States / cities: Anniston, Alabama • San Diego, California • Torrance, California + 3 more

Conditions: Endothelial Function, Oxidative Stress, Inflamation, Vascular Health
Interventions: Cocoa Flavanol Supplement, Low-Flavanol Control Powder; Dietary Supplement
Lead sponsor: The Black Forest LLC; Industry
Eligibility: 30 Years to 75 Years · Male only
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Miami, Florida

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Fluticasone Furoate (FF)/GW642444 Inhalation Powder, placebo; Drug · Device
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 8
States / cities: DeLand, Florida • Orlando, Florida • Madisonville, Kentucky + 5 more

Conditions: Chronic Obstructive Pulmonary Disease COPD
Interventions: Glycopyrronium/Formoterol Fumarate, umeclidinium/vilanterol; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years to 95 Years
Enrollment: 1,119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 15
States / cities: Tempe, Arizona • Escondido, California • Sacramento, California + 12 more

Conditions: Cardiovascular Disease, Oxidative Stress
Interventions: Chokeberry Extract, Placebo capsule, Chokeberry extract capsule, acute; Dietary Supplement
Lead sponsor: University of Connecticut; Other
Eligibility: 18 Years to 65 Years
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Storrs, Connecticut

Conditions: Anemia, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Low to Intermediate-1 MDS, Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML)
Interventions: Sotatercept; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 13
States / cities: Denver, Colorado • Tampa, Florida • Baltimore, Maryland + 10 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: FDC tiotropium / salmeterol, Placebo, Salmeterol, Tiotropium (Spiriva®); Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years and older
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 20
States / cities: Boulder, Colorado • Wheat Ridge, Colorado • Winter Park, Florida + 16 more

Conditions: Healthy Adults
Interventions: Antibiotic, HMO Concentrate, Probiotic, Food Supplement; Dietary Supplement
Lead sponsor: Prolacta Bioscience; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 92 participants
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Cypress, California

Conditions: Hypoglycemia, Diabetes Mellitus, Drug-Specific Antibodies
Interventions: Nasal Glucagon; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 3
States / cities: Waltham, Massachusetts • Minneapolis, Minnesota • Albany, New York

Search by objective public record fields.

Clinical Study to Evaluate the Efficacy and Safety of VR506 Using a New Inhaler for the Treatment of Asthma

A Clinical Study to Evaluate the Effect of the Connected Inhaler System (CIS) on Adherence to Maintenance Therapy in Poorly Controlled Asthmatic Subjects

A Repeat Dose Pharmacokinetic (PK) and Safety Study of GSK2838232 With and Without Ritonavir (RTV) Conducted in Healthy Subjects

PM14 Administered Intravenously to Patients With Advanced Solid Tumors

Effects of EED on Zn Absorption and Retention in Children From a MNP

Metformin Therapy for Overweight Adolescents With Type 1 Diabetes

PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC Patients

Aplidin - Dexamethasone in Relapsed/Refractory Myeloma

Phase 2b Study to Investigate the Safety and Efficacy of TIN816 in Sepsis-associated Acute Kidney Injury (CLEAR-AKI)

Safety and Effectiveness of D-serine in Schizophrenia

A Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in Participants With Advanced Solid Tumors

Dose Finding Study of [177Lu]Lu-NeoB in Newly Diagnosed Glioblastoma and in Recurrent Glioblastoma

Open-label Extension Study of GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)

A Study to Assess the Efficacy, Safety and Tolerability of IRL201104 in Adults With Active Eosinophilic Esophagitis

Safety and Efficacy of Indacaterol Once Daily Versus Salmeterol Twice Daily in Chronic Obstructive Pulmonary Disease (COPD)

Efficacy and Safety of NVA237 in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Black Forest Cocoa Flavanol Supplementation and Health Trial

A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetic (PK), and Pharmacodynamic (PD) Profiles of 3 Doses of Fluticasone Furoate (FF)/GW642444 Inhalation Powder at the End of a 28-day Treatment Period in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Compared to Placebo

Efficacy and Safety of Glycopyrronium/Formoterol Fumarate Fixed-dose Combination Relative to Umeclidinium/Vilanterol Fixed-dose Combination Over 24 Weeks in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

Study of Chokeberry to Reduce Cardiovascular Disease Risk in Former Smokers

Study of Sotatercept for the Treatment of Anemia in low-or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) or Non-proliferative Chronic Myelomonocytic Leukemia (CMML)

Tiotropium/Salmeterol Inhalation Powder (Spiriva Handihaler and Salmeterol Polyethylene (PE) Capsule) in Chronic Obstructive Pulmonary Disease (COPD)

Dietary Supplement With and Without a Probiotic and/or Antibiotic

Clinical Usability of Intranasal Glucagon in Treatment of Hypoglycemia